Publications en collaboration avec des chercheurs de Universidad de Salamanca (126)

2024

  1. Synergistic effects of medicinal plants in combination with spices from algeria: Anticancer, antiangiogenic activities, and embrytoxicity studies

    Journal of Ethnopharmacology, Vol. 330

  2. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2023

  1. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

    Cancer Letters, Vol. 554

  2. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

    Biomolecules, Vol. 12, Núm. 11

  2. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

2020

  1. Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis

    Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151

  2. Letter to the editor: What about incorporating selenium in the therapeutic regimen of SARS-CoV-2?

    EXCLI Journal

  3. Medicinal Plants as Sources of Active Molecules Against COVID-19

    Frontiers in Pharmacology, Vol. 11

  4. What about incorporating vitamins D and C supplementation in the prevention and treatment of COVID-19? The immune response pathway

    Mediterranean Journal of Nutrition and Metabolism

2019

  1. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

    Frontiers in Immunology, Vol. 10

  2. Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA-MB 231 breast cancer cells

    Molecular Medicine Reports, Vol. 20, Núm. 1, pp. 73-80

  3. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

    Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701

  4. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

    OncoImmunology, Vol. 8, Núm. 10

  5. MEK5 promotes lung adenocarcinoma

    The European respiratory journal

  6. Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors

    Nanomaterials, Vol. 9, Núm. 7

  7. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis

    Cancer Treatment Reviews, Vol. 77, pp. 11-19

2018

  1. A Small Molecule Tubulin Depolymerizing Agent Identified by a Phenotypic Drug Discovery Approach

    Journal of Molecular and Clinical Medicine, Vol. 1, Núm. 2, pp. 67-76

  2. Colorectal cancer and medicinal plants: Principle findings from recent studies

    Biomedicine and Pharmacotherapy, Vol. 107, pp. 408-423

  3. Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia [Oncotarget, 8 (2017) (29679-29698)] Doi: 10.18632/oncotarget.11425

    Oncotarget